Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-03-06
2010-11-09
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S388100
Reexamination Certificate
active
07829086
ABSTRACT:
The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5831142 (1998-11-01), Tedder
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6022521 (2000-02-01), Wahl et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung et al.
patent: 6251362 (2001-06-01), Wahl et al.
patent: 6254868 (2001-07-01), Leung et al.
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6399061 (2002-06-01), Anderson et al.
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 6921846 (2005-07-01), Tedder
patent: 2002/0071807 (2002-06-01), Goldenberg
patent: 2003/0124058 (2003-07-01), Goldenberg
patent: 2003/0133930 (2003-07-01), Goldenberg et al.
patent: 2003/0202975 (2003-10-01), Tedder et al.
patent: 2004/0001828 (2004-01-01), Tuscano et al.
patent: 2004/0202658 (2004-10-01), Benyunes
patent: 2004/0219156 (2004-11-01), Goldenberg et al.
patent: 2005/0118182 (2005-06-01), Pastan et al.
patent: 2007/0264260 (2007-11-01), Tuscano et al.
patent: 2008/0118505 (2008-05-01), Tedder
patent: 0 660 721 (2008-10-01), None
patent: WO 03/093320 (2003-11-01), None
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
De Pascalis et al. (The Journal of Immunology (2002) 169, 3076-3084).
Casset et al. ((2003) BBRC 307, 198-205).
Vajdos et al. ((2002) J. Mol. Biol. 320, 415-428).
Holm et al ((2007) Mol. Immunol. 44: 1075-1084).
Chen et al. (J. Mol. Bio. (1999) 293, 865-881).
Wu et al. (J. Mol. Biol. (1999) 294, 151-162).
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
U.S. Appl. No. 11/715,307, filed Mar. 6, 2007, Jones et al.
Friedberg, 2004, “Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era”, Clin Cancer Res. 10(16):5297-5298.
Ghetie et al., 1991, “Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites”, Cancer Res. 51(21):5876-5880.
Ghetie et al., 1992, “The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin”, Blood 80(9):2315-2320.
Ghetie et al., 1996, “Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma”, Int. J. Cancer 68(1):93-96.
Goldenberg et al., 1990, “Monoclonal antibody therapy of cancer”, N. J. Med. 87(11 Spec No):913-918.
Goldenberg, 1994, “New developments in monoclonal antibodies for cancer detection and therapy”, CA Cancer J. Clin. 44(1):43-64.
Haas et al., 2006, “CD22 regulates normal and malignant B survival in vivo”, J. Immunol. 177:3063-3073.
Hekman et al., 1991, “Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody”, Cancer Immunol. Immunother. 32(6):364-372 (1991).
Jacobsen et al., 1997, “Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States”, Clin Immunol. Imnunopathol. 84:223-243.
Juweid et al., 1995, “Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody”, Cancer Res. 55(23 Suppl):5899s-5907s.
Kaminski et al., 1993, “Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody”, N. Eng. J. Med. 329:459-465.
Khazaeli et al., 1994, “Low V-region immunogenicity of therapeutic doses of 1311-LL2 mouse monoclonal antibody in lymphoma patients”, J. Immunother. 16(2):170 (abstract No. 89).
Kreitman et al., 1993, “Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice”, Cancer Res. 53(4):819-825.
Leandro et al., 2002, “Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion”, Ann. Rheum. Dis. 61:883-888.
Leblond et al., 1995, “Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center”, J. Clin. Oncol. 13(4):961-968.
Leonard et al., 1999, “Epratuzumab, a new anti-CD22, humanized, monoclonal antibody, for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results”, Blood 94(suppl. 1, aprt I): 92a-93a, Abstract No. 404 (1999).
Leonard et al., 2003, “Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma”, J. Clin. Oncol. 21(16):3051-3059.
Leonard et al., 2004, “Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results”, Clin. Cancer Res. 10(16):5327-5334.
Leonard et al., 2005, “Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma”, J. Clin. Oncol. 23(22):5044-5051; Epub Jun. 13, 2005.
Leung et al., 1994, “Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma”, Hybridoma 13(6):469-476 (1994).
Leung et al., 1995, “Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2”, Mol. Immunol. 32(17-18):1413-1427 (1995).
Linden et al., 2005, “Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab”, Clin. Cancer Res. 11(14):5215-5222.
Losman et al., 1997, “Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2)”, Cancer 80(12 Suppl):2660-2666.
Maloney et al., 1997, “IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma”, J. Clin. Oncol. 15:3266-3274.
Maloney et al.
Hilbert David M.
Jones Tarran
Williams David G.
Aeres Biomedical, Ltd.
Bristol Lynn
Jones Day
Medimmune, LLC
LandOfFree
Humanized anti-CD22 antibodies and their use in treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-CD22 antibodies and their use in treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-CD22 antibodies and their use in treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157946